Fig. 7.

Antitumor activity of a BTZ/trametinib regimen in vivo. Mice with U266 cells expressing CA-G12V-NRAS (A) and treated with vehicle, trametinib, BTZ, or the combination were subjected to whole animal in vivo imaging. Tumor burden as represented by mean total flux (emitted photons per second) was plotted according to time ± SD of triplicates with asterisks indicating P < 0.05 versus the vehicle controls. A similar experiment but with mice bearing DN-S17N-NRAS (B) was also shown as are whole animal images for both groups (C) from week 7.